In addition, this approach activating the Wnt/β-catenin signaling, not by direct activation, but by release of the suppressed Wnt/β-catenin signaling by blockade of a negative feedback mechanism by CXXC5 could provide a safe anti-obesity approach effect which is a major huddle in the development of anti-obesity drugs and targeting the Wnt/β-catenin pathway. The gene discussed is CXXC5; the disease is obesity due to melanocortin 4 receptor deficiency.